摘要
目的探讨孟鲁司特钠片联合硫酸特布他林雾化液治疗小儿肺炎支原体感染并发咳嗽变异性哮喘(CVA)的临床疗效。方法选取医院2014年1月至2015年12月收治的肺炎支原体感染并发CVA患儿164例,随机分为两组,各82例。在常规抗感染治疗基础上,对照组患儿予硫酸特布他林雾化吸入治疗,观察组患儿予硫酸特布他林雾化联合口服孟鲁司特钠片治疗,均治疗3个月。结果观察组患儿咳嗽消失时间、肺罗音消失时间、体温恢复正常时间、X线摄片阴影消失时间均明显短于对照组(P<0.05);两组患儿肺功能均较治疗前明显改善,且观察组改善更明显(P<0.05);观察组临床总有效率为97.56%,高于对照组的78.05%(P<0.05)。结论孟鲁司特钠片联合硫酸特布他林雾化液治疗小儿肺炎支原体感染并发CVA临床疗效显著,较单用硫酸特布他林雾化液改善临床症状、体征的时间更短,值得临床推广。
Objective To investigate the clinical effect of Montelukast Sodium Tablets combined with Terbutaline Sulphate Solution for Nebulization in the treatment of children patients with mycoplasma pneumoniae infection complicated with cough variant asthma. Methods Totally 164 children patients with mycoplasma pneumoniae infection complicated with cough variant asthma admitted to our hospital from January 2014 to December 2015 were selected and randomly divided into two groups,82 cases in each group. On the basis of routine anti-infection treatment,the control group was treated with atomization inhalation of terbutaline,while the observation group was treated with atomization inhalation of terbutaline sulphate combined with Montelukast Sodium Tablets. The two groups were treated for 3 months. Results The cough disappeared time, the pulmonary rales disappeared time, body temperature recovery time, X-ray shadow disappear time in observation group were significantly shorter than those in the control group( P 0. 05). The lung function of the two groups was significantly improved compared with those before treatment, and the improvement of the observation group was more sig nifi cant( P 0. 05). The total effective rate of the observation group was 97. 56 %, which was significantly higher than78. 05 % of the control group( P 0. 05). Conclusion Montelukast Sodium Tablets combined with Terbutaline Sulphate Solution for Nebulization in the treatment children patients with mycoplasma pneumoniae infection complicated with cough variant asthma have a significant effect. Compared with Terbutaline Sulphate Solution for Nebulization alone,their time for improving clinical symptoms and signs is shorter,which are worthy of clinical promotion.
作者
张益民
曹阳
郭桂梅
Zhang Yimin;Cao Yang;Guo Guimei(Shanghai Children's Hospital,Shanghai,China 20004)
出处
《中国药业》
CAS
2018年第13期59-61,共3页
China Pharmaceuticals
关键词
孟鲁司特钠
特布他林
支原体感染
哮喘
咳嗽
montelukast sodium
terbutaline
mycoplasma infections
asthma
cough